A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer.

Kondo, Ken; Sakamoto, Juichi; Nakazato, Haruki; Koike, Akihiko; Kitoh, Tomoko; Hachisuka, Kitao; Saji, Shigetoyo; Yura, Jiro; Nimura, Yuji; Hamajima, N.; Katoh, Kazuo; Yamaguchi, Akio; Miya, Kiichi; Yamauchi, Masaji; Mizuno, Ishikazu; Nagino, Masato; Takagi, H

doi:10.3892/or.7.3.485

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single trial that enrolled patients with cardiac arrest has reported ICU-free survival during the first month after cardiac arrest. 19 Importantly, hospital-free survival has been used as an outcome in randomized trials in patients with heart failure, 20,21 renal failure, 22 cancer, 23 or need for intensive care. 24 As well, hospital-free survival is recommended as an outcome in trials that enroll patients with need for intensive care.…”

Section: Discussionmentioning

confidence: 99%

What change in outcomes after cardiac arrest is necessary to change practice? Results of an international survey

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

What change in outcomes after cardiac arrest is necessary to change practice? Results of an international survey

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[6][7][8] 1-(2-Tetrahydrofuryl)-5-fluorouracil (FT), 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5Ј-deoxy-5-fluorouridine (5Ј-DFUR) are synthetic derivatives of 5-FU. [9][10][11][12][13] UFT is a mixed compound of tegafur and uracil at a ratio of 1 : 4. 14) FT is converted to 5-FU by the microsomal fraction (P-450) of liver in the presence of NADPH.…”

Section: -Fluorouracil (5-fu) Synthesized In 1956 Bymentioning

confidence: 99%

Plasma, Intestine and Tumor Levels of 5-Fluorouracil in Mice Bearing L1210 Ascites Tumor Following Oral Administration of 5-Fluorouracil, UFT (Mixed Compound of Tegafur and Uracil), Carmofur and 5'-Deoxy-5-fluorouridine.

Ooi

Ohkubo

Higashigawa

et al. 2001

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

“…Free-days outcomes (i.e. the total number of days alive and free of a supportive therapy) are increasingly used for critical care clinical trials [ 1 , 12 ] and for trials in other medical conditions [ 18 – 21 ]. While standard definitions for calculating free-days outcomes exist, there is some variation from clinical trial to clinical trial [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Exploration of alive-and-ventilator free days as an outcome measure for clinical trials of Resuscitative interventions

Moskowitz,

Xie,

Gong

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Outcome selection is a critically important aspect of clinical trial design. Alive-and-ventilator free days is an outcome measure commonly used in critical care clinical trials, but has not been fully explored in resuscitation science. Methods A simulation study was performed to explore approaches to the definition and analysis of alive-and-ventilator free days in cardiac arrest populations. Data from an in-hospital cardiac arrest observational cohort and from the Pragmatic Airway Resuscitation Trial were used to inform and conduct the simulations and validate approaches to alive-and-ventilator free days measurement and analysis. Findings Alive-and-ventilator-free days is a flexible outcome measure in cardiac arrest populations. An approach to alive-and-ventilator free days that assigns -1 days when return of spontaneous circulation is not achieved provides a wider distribution of the outcome and improves statistical power. The optimal approach to the analysis of alive-and-ventilator free days varies based on the expected impact of the intervention under study on rates of return of spontaneous circulation, survival, and ventilator-free survival. Conclusions Alive-and-ventilator free days adds to the armamentarium of clinical trialists in the field of resuscitation science.

show abstract

A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer.

Cited by 6 publications

References 0 publications

What change in outcomes after cardiac arrest is necessary to change practice? Results of an international survey

What change in outcomes after cardiac arrest is necessary to change practice? Results of an international survey

Plasma, Intestine and Tumor Levels of 5-Fluorouracil in Mice Bearing L1210 Ascites Tumor Following Oral Administration of 5-Fluorouracil, UFT (Mixed Compound of Tegafur and Uracil), Carmofur and 5'-Deoxy-5-fluorouridine.

Exploration of alive-and-ventilator free days as an outcome measure for clinical trials of Resuscitative interventions

Contact Info

Product

Resources

About